Randomized, sham-controlled trial of intraoperative ticagrelor removal to reduce perioperative bleeding
The Journal of Thoracic and Cardiovascular Surgery · 2026-07 · 172 (1) · 128-137.e4
DOI: 10.1016/j.jtcvs.2026.01.012 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2026-07. Verfasst von Michael J Mack und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Surgery, Baylor Scott & White Health, Dallas, Tex. Electronic address: Michael.mack@BSWHealth.org. Hauptthemen laut MEDLINE: Ticagrelor, Coronary Artery Bypass, Postoperative Hemorrhage, Blood Loss, Surgical. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
OBJECTIVE: Patients on ticagrelor who are undergoing cardiac surgery before completing guideline-recommended washout are at high risk for severe bleeding. This study evaluated whether a novel drug removal device reduces bleeding in patients operated within 2 days from ticagrelor discontinuation. METHODS: Eligible patients were randomized 1:1 to intraoperative DrugSorb-ATR or sham control. Primary safety end point was adverse events at 30 days. Efficacy was assessed by composite end points comprising bleeding events using Universal Definition of Perioperative Bleeding (UDPB) and 24-hour chest tube drainage (CTD) in the overall and isolated coronary artery bypass grafting (CABG) populations with a hierarchical win ratio (WR) method. RESULTS: In total, 140 patients were randomized; 132 had surgery and received a study device; and 92% were isolated CABG. Mean age was 65 ± 5 years, and 15% were female. The primary safety end point was met, with similar adverse events reported between groups. The primary efficacy end point was not met in the overall or CABG populations (Win ratio [WR], 1.07; 95% CI, 0.72-1.58; P = .748 and WR, 1.33; 95% CI, 0.86-2.04; P = .202 respectively). The supplementary efficacy end point was met in the CABG population (WR, 1.59; 95% CI, 1.02-2.46, P = .041) with significant reductions also shown in large CTD bleeding events (P = .016) and major bleeding, a composite of severe bleeding events or 24-hour CTD ≥1 L (P = .041). The number needed to treat to prevent a major bleed was 6. CONCLUSIONS: Intraoperative use of DrugSorb-ATR is safe in patients operated within 2 days of ticagrelor discontinuation. Although the primary end point was not met in the overall population, there were significant reductions in severe bleeding events in the prespecified CABG population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Surgery, Baylor Scott & White Health, Dallas, Tex. Electronic address: Michael.mack@BSWHealth.org.
- Cardiovascular Surgery, Population Health Research Institute, Hamilton, Canada.
- Division of Cardiac Surgery, Western University, London Health Sciences Centre, London, Canada.
- Division of Cardiac Surgery, University of Maryland Medical Center, Baltimore, Md.
- Department of Cardiothoracic Surgery, NYU Langone School of Medicine, New York, NY.
- Department of Cardiac Surgery, Beth Israel Deaconess Medical Center, Boston, Mass.
Zitieren
APA
Mack, M. J., Whitlock, R., Chu, M. W. A., Taylor, B., Zias, E. A., Liu, D., Protos, A. N., Rokkas, C., Pelletier, M., Choi, C. W., Saha, T., Sellke, F. W., Schneider, D. J., Thourani, V. H., Douketis, J., Mazer, C. D., Fan, W., Deliargyris, E. N., Gibson, C. M., & Safe and Timely Antithrombotic Removal-Ticagrelor (STAR-T) Investigators (2026). Randomized, sham-controlled trial of intraoperative ticagrelor removal to reduce perioperative bleeding. The Journal of Thoracic and Cardiovascular Surgery, 172(1), 128-137.e4. https://doi.org/10.1016/j.jtcvs.2026.01.012
Vancouver
Mack MJ, Whitlock R, Chu MWA, Taylor B, Zias EA, Liu D, et al. Randomized, sham-controlled trial of intraoperative ticagrelor removal to reduce perioperative bleeding. The Journal of Thoracic and Cardiovascular Surgery. 2026;172(1):128-137.e4. doi:10.1016/j.jtcvs.2026.01.012
BibTeX
@article{Mack2026,
author = {Mack, Michael J and Whitlock, Richard and Chu, Michael W A and Taylor, Bradley and Zias, Elias A and Liu, David and Protos, Adam N and Rokkas, Chris and Pelletier, Marc and Choi, Chun W and Saha, Tarit and Sellke, Frank W and Schneider, David J and Thourani, Vinod H and Douketis, James and Mazer, Cyril David and Fan, Weihong and Deliargyris, Efthymios N and Gibson, Charles Michael and Safe and Timely Antithrombotic Removal-Ticagrelor (STAR-T) Investigators, Safe and Timely Antithrombotic Removal-Ticagrelor (STAR-T) Investigators},
title = {Randomized, sham-controlled trial of intraoperative ticagrelor removal to reduce perioperative bleeding},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2026},
volume = {172},
number = {1},
pages = {128--137.e4},
doi = {10.1016/j.jtcvs.2026.01.012}
}
EUVIMED